Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Multicenter Study of Orally Administered RVU120 for the Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms (MDS)

NCT06243458 is registered in ClinicalTrials.gov with GCP-Service International West GmbH as lead sponsor.

NCT NCT06243458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06243458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Multicenter Study of Orally Administered RVU120 for the Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms (MDS)
Lead sponsor
GCP-Service International West GmbH
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 10, 2024
Completion date
May 31, 2027
Enrollment
41 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

low risk myelodysplastic syndromes